References
- Bunin GR, Surawicz TS, Witman PA, Preston-Martin S, Davis F, Bruner JM. The descriptive epidemiology of craniopharyngioma. J Neurosurg 1998; 89: 547-51. doi: 10.3171/jns.1998.89.4.0547
- Nielsen EH, Feldt-Rasmussen U, Poulsgaard L, Kristensen LO, Astrup J, Jorgensen JO, et al. Incidence of craniopharyngioma in Denmark (n = 189) and estimated world incidence of craniopharyngioma in children and adults. J Neurooncol 2011; 104: 755-63. doi: 10.1007/s11060-011-0540-6
- Ostrom QT, Gittleman H, Liao P, Vecchione Koval T, Wolinsky Y, Kruchko C, et al. CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010–2014. Neuro Oncol 2017; 19(Suppl. 5): 1-88. doi: 10.1093/neuonc/nox158
- Ostrom QT, Gittleman H, Xu J, Kromer C, Wolinsky Y, Kruchko C, et al. CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2009-2013. Neuro Oncol 2016; 18: 1-75. doi: 10.1093/neuonc/now207
- Thapar, K, Kovacs K. Neoplasms of the sellar region. Russell and Rubinstein’s Pathology of Tumors of the Nervous System, 6th Edn. 1998: 629-80.
- Zada G, Lin N, Ojerholm E, Ramkissoon S, Laws ER. Craniopharyngioma and other cystic epithelial lesions of the sellar region: a review of clinical, imaging, and histopathological relationships. Neurosurg Focus 2010; 28: E4. doi: 10.3171/2010.2.FOCUS09318
- Pascual JM, Prieto R, Rosdolsky M, Strauss S, Castro I, Verena D. Cystic tumors of the pituitary infundibulum : seminal autopsy specimens (1899 to 1904) that allowed clinical-pathological craniopharyngioma characterization. Pituitary 2018; 21: 393-405. doi:10.1007/s11102-018-0889-z
- Wijnen M, Van Den Heuvel-Eibrink MM, Janssen JAMJL, Catsman-Berrevoets CE, Michiels EMC, Van Veelen-Vincent MLC, et al. Very long-Term sequelae of craniopharyngioma. Eur J Endocrinol 2017; 176: 755-67. doi: 10.1530/EJE-17-0044
- Sterkenburg AS, Hoffmann A, Gebhardt U, Warmuth-Metz M, Daubenbüchel AMM, Müller HL. Survival, hypothalamic obesity, and neuropsychological/psychosocial status after childhood-onset craniopharyngioma: Newly reported long-term outcomes. Neuro Oncol 2015; 17: 1029-38. doi: 10.1093/neuonc/nov044
- Erfurth EM, Holmer H, Fjalldal SB. Mortality and morbidity in adult craniopharyngioma. Pituitary 2013; 16: 46-55. doi: 10.1007/s11102-012-0428-2
- Müller HL, Merchant TE, Puget S, Martinez-Barbera JP. New outlook on the diagnosis, treatment and follow-up of childhood-onset craniopharyngioma. Nat Rev Endocrinol 2017; 13: 299-312. doi: 10.1038/nrendo.2016.217
- Heinks K, Boekhoff S, Hoffmann A, Warmuth-Metz M, Eveslage M, Peng J, et al. Quality of life and growth after childhood craniopharyngioma: results of the multinational trial KRANIOPHARYNGEOM 2007. Endocrine 2018; 59: 364-372. doi: 10.1007/s12020-017-1489-9
- Karavitaki N, Brufani C, Warner JT, Adams CBT, Richards P, Ansorge O, et al. Craniopharyngiomas in children and adults: Systematic analysis of 121 cases with long-term follow-up. Clin Endocrinol (Oxf) 2005; 62: 397-409. doi: 10.1111/j.1365-2265.2005.02231.x
- Muller HL. Craniopharyngeoma - a chronic disease. Swiss Med Wkly 2018; 148: w14548. doi: 10.4414/smw.2017.14548
- Schoenfeld A, Pekmezci M, Barnes MJ, Tihan T, Gupta N, Lamborn KR, et al. The superiority of conservative resection and adjuvant radiation for craniopharyngiomas. J Neurooncol 2012; 8: 133-9. doi: 10.1007/s11060-012-0806-7
- Hoffmann A, Warmuth-Metz M, Gebhardt U, Müller H. Childhood Craniopharyngioma – Changes of Treatment Strategies in the Trials KRANIOPHARYNGEOM 2000/2007. Klin Padiatr 2014; 226: 161-8. doi:10.1055/s-0034-1368785
- Ajithkumar T, Mazhari AL, Stickan-Verfürth M, Kramer PH, Fuentes CS, Lambert J, et al. Proton Therapy for Craniopharyngioma — An Early Report from a Single European Centre. Clin Oncol 2018; 30: 307-16. doi: 10.1016/j. clon.2018.01.012
- Kendall-Taylor P, Jönsson PJ, Abs R, Erfurth EM, Koltowska-Häggström M, Price DA, et al. The clinical, metabolic and endocrine features and the quality of life in adults with childhood-onset craniopharyngioma compared with adult-onset craniopharyngioma. Eur J Endocrinol 2005; 152: 557-67. doi: 10.1530/eje.1.01877
- Wijnen M, Olsson DS, Van Den Heuvel-Eibrink MM, Hammarstrand C, Janssen JAMJL, Van Der Lely AJ, et al. The metabolic syndrome and its components in 178 patients treated for craniopharyngioma after 16 years of follow-up. Eur J Endocrinol 2018; 178: 11-22. doi: 10.1530/EJE-17-0387
- Andereggen L, Hess B, Andres RH, El-Koussy M, Mariani L, Raabe A, et al. A ten-year follow-up study of treatment outcome of craniopharyngiomas. Swiss Med Wkly 2018; 148: 1-8. doi: 10.4414/smw.2017.14521
- Tan TSE, Patel L, Gopal-Kothandapani JS, Ehtisham S, Ikazoboh EC, Hayward R, et al. The neuroendocrine sequelae of paediatric craniopharyngioma: A 40-year meta-data analysis of 185 cases from three UK centres. Eur J Endocrinol 2017; 176: 359-69. doi: 10.1530/EJE-16-0812
- Bosnjak R, Benedicic M, Vittori A. Early outcome in endoscopic extended endonasal approach for removal of supradiaphragmatic craniopharyngiomas: A case series and a comprehensive review. Radiol Oncol 2013; 47: 266-79. doi: 10.2478/raon-2013-0036
- Brastianos PK, Shankar GM, Gill CM, Taylor-Weiner A, Nayyar N, Panka, DJ, et al. Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy. J Natl Cancer Inst 2016; 108: 1-5. doi: 10.1093/jnci/djv310
- Himes BT, Ruff MW, Gompel JJ Van, Park SS, Galanis E, Kaufmann TJ, et al. Recurrent papillary craniopharyngioma with Dabrafenib: case report. J Neurosurg 2018; 1: 1-5. doi: 10.3171/2017.11.JNS172373
- Hoffmann A, Boekhoff S, Gebhardt U, Sterkenburg AS, Daubenbüchel AMM, Eveslage M, et al. History before diagnosis in childhood craniopharyngioma: Associations with initial presentation and long-term prognosis. Eur J Endocrinol 2015; 173: 853-62. doi: 10.1530/EJE-15-0709
- Mortini P, Losa M, Pozzobon G, Barzaghi R, Riva M, Acerno S, et al. Neurosurgical treatment of craniopharyngioma in adults and children: early and long-term results in a large case series. J Neurosurg 2011; 114: 1350-9. doi: 10.3171/2010.11.JNS10670
- Crotty TB, Scheithauer BW, Young WF, Davis DH, Shaw EG, Miller GM, et al. Papillary craniopharyngioma: a clinicopathological study of 48 cases. J Neurosurg 1995; 83: 206-14. doi: 10.3171/jns.1995.83.2.0206
- Müller HL. Hypothalamic involvement in craniopharyngioma—Implications for surgical, radiooncological, and molecularly targeted treatment strategies. Pediatr Blood Cancer 2018; 65: e26936. doi: 10.1002/pbc.26936
- Roth CL, Eslamy H, Werny D, Elfers C, Shaffer ML, Pihoker C, et al. Semiquantitative analysis of hypothalamic damage on MRI predicts risk for hypothalamic obesity. Obesity 2015; 23: 1226-33. doi: 10.1002/oby.21067
- Mortini P, Gagliardi F, Bailo M, Spina A, Parlangeli A, Falini A, et al. Magnetic resonance imaging as predictor of functional outcome in craniopharyngiomas. Endocrine 2016; 51: 148-62. doi: 10.1007/s12020-015-0683-x
- Müller HL. Craniopharyngioma and hypothalamic injury: Latest insights into consequent eating disorders and obesity. Curr Opin Endocrinol Diabetes Obes 2016; 23: 81-9. doi: 10.1097/MED.0000000000000214
- Pascual JM, Prieto R, Carrasco R, Barrios L. Displacement of mammillary bodies by craniopharyngiomas involving the third ventricle: surgical-MRI correlation and use in topographical diagnosis. J Neurosurg 2013; 119: 381-405. doi: 10.3171/2013.1.JNS111722
- Zoicas F, Schöfl C. Craniopharyngioma in Adults. Front Endocrinol (Lausanne) 2012; 3: 46. doi: 10.3389/fendo.2012.00046
- Amelot A, Borha A, Calmon R, Barbet P, Puget S. Child dermoid cyst mimicking a craniopharyngioma: the benefit of MRI T2-weighted diffusion sequence. Child’s Nerv Syst 2018; 34: 359-62. doi: 10.1007/s00381-017-3602-z
- Puget S, Garnett M, Wray A, Grill J, Habrand JL, Bodaert N, et al. Pediatric craniopharyngiomas: classification and treatment according to the degree of hypothalamic involvement. J Neurosurg Pediatr 2007; 106: 3-12. doi: 10.3171/ped.2007.106.1.3
- Elowe-Gruau E, Beltrand J, Brauner R, Pinto G, Samara-Boustani D, Thalassinos C, et al. Childhood craniopharyngioma: Hypothalamus-sparing surgery decreases the risk of obesity. J Clin Endocrinol Metab 2013; 98: 2376-82. doi: 10.1210/jc.2012-3928
- Weiner HL, Wisoff JH, Rosenberg ME, Kupersmith MJ, Cohen H, Zagzag D, et al. Craniopharyngiomas: A Clinicopathological Analysis of Factors Predictive of Recurrence and Functional Outcome. Neurosurgery 1994; 35: 1001-11. http://dx.doi.org/10.1227/00006123-199412000-00001
- Müller HL, Gebhardt U, Teske C, Faldum A, Zwiener I, Warmuth-Metz M, et al. Post-operative hypothalamic lesions and obesity in childhood craniopharyngioma: Results of the multinational prospective trial KRANIOPHARYNGEOM 2000 after 3-year follow-up. Eur J Endocrinol 2011; 165: 17-24. doi: 10.1530/EJE-11-0158
- Gu Y, Zhang X. Letter to the Editor: Mammillary body angle and craniopharyngioma. J Neurosurg 2014; 120: 1241-5. doi: 10.3171/2013.11.JNS132343
- Coury JR, Davis BN, Koumas CP, Manzano GS, Dehdashti AR. Histopathological and molecular predictors of growth patterns and recurrence in craniopharyngiomas: a systematic review. Neurosurg Rev 2018. doi: 10.1007/s10143-018-0978-5
- Karavitaki N, Cudlip S, Adams CB, and Wass JA. Craniopharyngiomas. Endocr Rev 2006; 27: 371-97. doi: 10.1210/er.2006-0002
- Clark AJ, Cage TA, Aranda D, Parsa AT, Sun PP, Auguste KI, et al. A systematic review of the results of surgery and radiotherapy on tumor control for pediatric craniopharyngioma. Child’s Nerv Syst 2013; 29: 231-8. doi: 10.1007/s00381-012-1926-2
- Kiehna EN, Merchant TE. Radiation therapy for pediatric craniopharyngioma. Neurosurg Focus 2010; 28: E10. doi: 10.3171/2010.1.FOCUS09297
- O’steen L, Indelicato DJ. Advances in the management of craniopharyngioma. F1000Research 2018; 7: 1632. doi:10.12688/f1000research.15834.1
- Kortmann RD. Different Approaches in Radiation Therapy of Craniopharyngioma. Front Endocrinol (Lausanne) 2011; 2: 100. doi: 10.3389/fendo.2011.00100
- Bishop AJ, Greenfield B, Mahajan A, Paulino AC, Okcu MF, Allen, PK, et al. Proton beam therapy versus conformal photon radiation therapy for childhood craniopharyngioma: Multi-institutional analysis of outcomes, cyst dynamics, and toxicity. Int J Radiat Oncol Biol Phys 2014; 90: 354-61. doi: 10.1016/j.ijrobp.2014.05.051
- Harrabi SB, Adeberg S, Welzel T, Rieken S, Habermehl D, Debus J, et al. Long term results after fractionated stereotactic radiotherapy (FSRT) in patients with craniopharyngioma: maximal tumor control with minimal side effects. Radiat Oncol 2014; 9: 203. doi: 10.1186/1748-717X-9-203
- Beltran C, Roca M, Merchant TE. On the Benefits and Risks of Proton Therapy in Pediatric Craniopharyngioma. Int J Radiat Oncol 2012; 82: 281-7. doi: 10.1016/j.ijrobp.2011.01.005
- Regine WF, Kramer S. Pediatric craniopharyngiomas: Long term results of combined treatment with surgery and radiation. Int J Radiat Oncol 1992; 24: 611-17. doi: 10.1016/0360-3016(92)90705-M
- Winkfield KM, Linsenmeier C, Yock TI, Grant PE, Yeap BY, Butler WE, et al. Surveillance of Craniopharyngioma Cyst Growth in Children Treated With Proton Radiotherapy Int J Radiat Oncol 2009; 73: 716-21. doi: https://doi.org/10.1016/j.ijrobp.2008.05.010
- Losa M, Pieri V, Bailo M, Gagliardi F, Barzaghi LR, Gioia L, et al. Single fraction and multisession Gamma Knife radiosurgery for craniopharyngioma. Pituitary 2018; 21: 499-506. doi: 10.1007/s11102-018-0903-5
- Buslei R, Nolde M, Hofmann B, Meissner S, Eyupoglu IY, Siebzehnrübl F, et al. Common mutations of β-catenin in adamantinomatous craniopharyngiomas but not in other tumours originating from the sellar region. Acta Neuropathol 2005; 109: 589-97. doi: 10.1007/s00401-005-1004-x
- Pekmezci M, Louie J, Gupta N, Bloomer MM, Tihan T. Clinicopathological characteristics of adamantinomatous and papillary craniopharyngiomas: University of California, San Francisco experience 1985-2005. Neurosurgery 2010; 67: 1341-9. doi: 10.1227/NEU.0b013e3181f2b583
- Prieto R, Pascual JM. Can tissue biomarkers reliably predict the biological behavior of craniopharyngiomas? A comprehensive overview. Pituitary 2018; 21: 431-42. doi: 10.1007/s11102-018-0890-6
- Apps JR, Martinez-Barbera JP. Molecular pathology of adamantinomatous craniopharyngioma: review and opportunities for practice. Neurosurg Focus 2016; 41: E4. doi: 10.3171/2016.8.FOCUS16307
- Brastianos PK, Taylor-Weiner A, Manley PE, Robert T, Dias-Santagata D, Thorner AR, et al. Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas. Nat Genet 2014; 46: 161-5. doi: 10.1038/ng.2868
- Apps JR, Carreno G, Gonzalez-Meljem JM, Haston S, Guiho R, Cooper JE, et al. Tumour compartment transcriptomics demonstrates the activation of inflammatory and odontogenic programmes in human adamantinomatous craniopharyngioma and identifies the MAPK/ERK pathway as a novel therapeutic target. Acta Neuropathol 2018; 135: 757-77. doi: 10.1007/s00401-018-1830-2
- Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949. doi: 10.1038/nature00766
- Larkin SJ, Preda V, Karavitaki N, Grossman A, Ansorge O. BRAF V600E mutations are characteristic for papillary craniopharyngioma and may coexist with CTNNB1-mutated adamantinomatous craniopharyngioma. Acta Neuropathol 2014; 127: 927-9. doi: 10.1007/s00401-014-1270-6
- Bi WL, Larsen AG, Dunn IF. Genomic Alterations in Sporadic Pituitary Tumors. Curr Neurol Neurosci Rep 2018; 18: 4. doi:10.1007/s11910-018-0811-0
- Aylwin SJB, Bodi I, Beaney R. Pronounced response of papillary craniopharyngioma to treatment with vemurafenib, a BRAF inhibitor. Pituitary 2016; 19: 544-6. doi: 10.1007/s11102-015-0663-4
- Roque A, Odia Y. BRAF-V600E mutant papillary craniopharyngioma dramatically responds to combination BRAF and MEK inhibitors. CNS Oncol 2017; 6: 95-9. doi: 10.2217/cns-2016-0034
- Rostami E, Witt Nyström P, Libard S, Wikström J, Casar-Borota O, Gudjonsson O. Recurrent papillary craniopharyngioma with BRAFV600E mutation treated with neoadjuvant-targeted therapy. Acta Neurochir (Wien) 2017; 159: 2217-21. doi: 10.1007/s00701-017-3311-0
- Caldarelli M, Massimi L, Tamburrini G, Cappa M, Di Rocco C. Long-term results of the surgical treatment of craniopharyngioma: the experience at the Policlinico Gemelli, Catholic University, Rome. Child’s Nerv Syst 2005; 21: 747-57. doi: 10.1007/s00381-005-1186-5
- Müller HL. Childhood craniopharyngioma. Pituitary 2013; 16: 56-67. doi: 10.1007/s11102-012-0401-0
- Boekhoff S, Bogusz A, Sterkenburg AS, Eveslage M, Müller HL. Long-term effects of growth hormone replacement therapy in childhood-onset craniopharyngioma: results of the German Craniopharyngioma Registry (HIT-Endo). Eur J Endocrinol 2018; 179: 331-41. doi: 10.1530/EJE-18-0505.
- Geffner ME. The growth without growth hormone syndrome. Endocrinol Metab Clin 1996; 25: 649-63. doi: 10.1016/S0889-8529(05)70345-5
- Holmer H, Pozarek G, Wirfält E, Popovic V, Ekman B, Björk J, et al. Reduced energy expenditure and impaired feeding-related signals but not high energy intake reinforces hypothalamic obesity in adults with childhood onset craniopharyngioma J Clin Endocrinol Metab 2010; 95: 5395-402. doi: 10.1210/jc.2010-0993
- Bereket A, Kiess W, Lustig RH, Müller HL, Goldstone AP, Weiss R, et al. Hypothalamic obesity in children. Obes Rev 2012; 13: 780-98. doi: 10.1111/j.1467-789X.2012.01004
- Hoffmann A, Bootsveld K, Gebhardt U, Daubenbüchel AMM, Sterkenburg AS, Müller HL. Nonalcoholic fatty liver disease and fatigue in long-term survivors of childhood-onset craniopharyngioma. Eur J Endocrinol 2015; 173: 389-97. doi: 10.1530/EJE-15-0422
- Tomlinson JW, Holden N, Hills RK, Wheatley K, Clayton RN, Bates AS, et al. Association between premature mortality and hypopituitarism. Lancet 2001; 357: 425-31. doi: 10.1016/S0140-6736(00)04006-X
- Rosén T, Bengtsson BA. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 1990; 336: 285-8. doi: 10.1016/0140-6736(90)91812-O
- Bülow B, Attewell R, Hagmar L, Malmström P, Nordström CH, Erfurth EM. Postoperative prognosis in craniopharyngioma with respect to cardiovascular mortality, survival, and tumor recurrence. J Clin Endocrinol Metab 1998; 83: 3897-904. doi: 10.1210/jc.83.11.3897
- Holmer H, Ekman B, Björk J, Nordstöm CH, Popovic V, Siversson AB, et al. Hypothalamic involvement predicts cardiovascular risk in adults with childhood onset craniopharyngioma on long-term GH therapy. Eur J Endocrinol 2009; 161: 671-9. doi: 10.1530/EJE-09-0449
- Defoort-Dhellemmes S, Moritz F, Bouacha I, Vinchon M. Craniopharyngioma: ophthalmological aspects at diagnosis. J Pediatr Endocrinol Metab 2006; 19(Suppl 1): 321-4. http://europepmc.org/abstract/MED/16700306
- Pierre-Kahn A, Recassens C, Pinto G, Thalassinos C, Chokron S, Soubervielle JC, et al. Social and psycho-intellectual outcome following radical removal of craniopharyngiomas in childhood. A prospective series. Child’s Nerv Syst 2005; 21: 817-24. doi: 10.1007/s00381-005-1205-6
- Riva D, Pantaleoni C, Devoti M, Saletti V, Nichelli F, Giorgi C. Late neuropsychological and behavioural outcome of children surgically treated for craniopharyngioma. Child’s Nerv Syst 1998; 14: 179-84. doi: 10.1007/s003810050207
- Özyurt J, Müller HL, Warmuth-Metz M, Thiel CM. Hypothalamic tumors impact gray and white matter volumes in fronto-limbic brain areas. Cortex 2017; 89: 98-110. doi: 10.1016/j.cortex.2017.01.017
- Poretti A, Grotzer MA, Ribi K, Schonle E, Boltshauser E. Outcome of craniopharyngioma in complications and quality of life. Dev Med Child Neurol 2004; 46: 220-9. doi: 10.1111/j.1469-8749.2004.tb00476.x
- Dekkers OM, Biermasz NR, Smith JWA, Groot LE, Roelfsema F, Romijn, JA, et al. Quality of life in treated adult craniopharyngioma patients. Eur J Endocrinol 2006; 154: 483-9. doi: 10.1530/eje.1.02114
- Gautier A, Godbout A, Grosheny C, Tejedor I, Coudert M, Courtillot C, et al. Markers of recurrence and long-term morbidity in craniopharyngioma: a systematic analysis of 171 patients. J Clin Endocrinol Metab 2012; 97: 1258-67. doi:10.1210/jc.2011-2817
- van Iersel L, Meijneke RWH, Schouten-van Meeteren AYN, Reneman L, de Win MM, van Trotsenburg ASP, et al. The development of hypothalamic obesity in craniopharyngioma patients: a risk factor analysis in a well-defined cohort. Pediatr Blood Cancer 2018; 65: e26911. doi: 10.1002/pbc.26911
- Borrill R, Cheesman E, Stivaros S, Kamaly-Asl ID, Gnanalingham K, Kilday J-P. Papillary craniopharyngioma in a 4-year-old girl with BRAF V600E mutation: a case report and review of the literature. Child’s Nerv Syst 2019; 35: 169-73. doi:10.1007/s00381-018-3925-4.